Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Non-Current Deffered Revenue (2016 - 2018)

Historic Non-Current Deffered Revenue for Altimmune (ALT) over the last 5 years, with Q4 2018 value amounting to $1.0 million.

  • Altimmune's Non-Current Deffered Revenue rose 17059.17% to $1.0 million in Q4 2018 from the same period last year, while for Dec 2018 it was $1.0 million, marking a year-over-year increase of 17059.17%. This contributed to the annual value of $1.0 million for FY2018, which is 17059.17% up from last year.
  • As of Q4 2018, Altimmune's Non-Current Deffered Revenue stood at $1.0 million, which was up 17059.17% from $1.1 million recorded in Q3 2018.
  • In the past 5 years, Altimmune's Non-Current Deffered Revenue registered a high of $1.1 million during Q2 2018, and its lowest value of $164609.0 during Q3 2017.
  • Its 3-year average for Non-Current Deffered Revenue is $661060.0, with a median of $716148.0 in 2017.
  • In the last 5 years, Altimmune's Non-Current Deffered Revenue surged by 11540.54% in 2017 and then skyrocketed by 56918.14% in 2018.
  • Quarter analysis of 3 years shows Altimmune's Non-Current Deffered Revenue stood at $179424.0 in 2016, then soared by 115.41% to $386489.0 in 2017, then surged by 170.59% to $1.0 million in 2018.
  • Its last three reported values are $1.0 million in Q4 2018, $1.1 million for Q3 2018, and $1.1 million during Q2 2018.